ELGX News and Press, Endologix Inc. From 04/15/19

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019. The Company’s management will ho...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "signifi...

"The average man does not want to be free. He simply wants to be safe ." - H.L. Mencken We continue our new weekly feature today. Every week we will be providing very brief overviews of some interesting stocks insiders are currently buying. I have always found insider buying one of best i...

Endologix (NASDAQ: ELGX ) has entered into a definitive agreement to raise ~$52M gross cash proceeds through the issuance of ~7.9M new common stock at a price of $6.61/share. More news on: Endologix, Inc., Healthcare stocks news, Stocks on the move, Read more ...

The Company reports preliminary revenue for the first quarter ending March 31, 2019 of at least $35 million The Company reiterates financial guidance for 2019 Transactions expected to close on or about April 3rd Endologix management to host conference call today a...

Endologix, Inc. (the “Company”) (NASDAQ: ELGX) previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation to effect a reverse stock spli...

Endologix Inc. (ELGX) Q4 2018 Earnings Conference Call February 25, 2019, 04:30 PM ET Company Participants John Onopchenko - CEO Vaseem Mahboob - CFO Conference Call Participants Chris Cooley - Stephens Mathew Blackman - Stifel Chris Hartstein - Guggenheim Presentation...

The following slide deck was published by Endologix Inc in conjunction with their 2018 Q4 earnings Read more ...

Endologix (NASDAQ: ELGX ) Q4 results ($M): Revenue: 34.7 (-21.1%). More news on: Endologix Inc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Endologix (NASDAQ: ELGX ): Q4 GAAP EPS of -$0.26 misses by $0.01 . More news on: Endologix Inc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...